From: Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
10% difference in score range
Mean baseline difference between ECOG performance scores 0 vs 1 to 2
Total FACT-MM
16.4
13.5
FACT-G
10.8
7.8
FACT-TOI
8.4
11.0
MM Domain
5.6
5.8